Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS/IC and uncomplicated recurrent urinary tract infections - Long-term results of a multicenter study.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
01 Nov 2019
Historique:
received: 25 04 2019
revised: 05 09 2019
accepted: 05 09 2019
pubmed: 10 9 2019
medline: 27 2 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

The purpose of this study is to evaluate the efficacy of intra-vesical instillations with hyaluronic acid (HA) in relieving lower urinary tract irritation symptoms in patients with urinary tract infections (UTIs) and bladder pain syndrome/interstitial cystitis (BPS/IC). This research, conducted in Romania, includes 30 patients with UTIs (Group I) and 24 with BPS/IC (Group II) as defined by European Association of Urology (EAU) Diagnostic Criteria. Data were collected prospectively, using pre- and post-treatment questionnaires for pelvic pain with a symptom scale for urination and frequency as well as visual analog scale (VAS) pain quizzes. At follow-up visits, at an average of 20 months, a significant improvement in urinary bladder pain, day-time urinary frequency and quality of life was observed in Group I patients. Group II patients experienced significant improvement in urinary bladder pain, urgency, nocturia and quality of life at the 15-month follow-up visit. Eighteen patients (75%) showed a complete response to intravesical HA instillations and required no further treatment. Our study demonstrates that intravesical HA instillations may be considered as an important treatment component, with long term positive effects in therapeutic strategy for optimal results in uncomplicated recurrent UTIs and BPS/IC, with good compliance and minimal side effects.

Identifiants

pubmed: 31499170
pii: S0928-0987(19)30338-0
doi: 10.1016/j.ejps.2019.105067
pii:
doi:

Substances chimiques

Hyaluronic Acid 9004-61-9

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

105067

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Ioan Scarneciu (I)

Department of Medical and Surgical Specialities, "Transilvania" University of Brasov, Brasov, Romania.

Simona Bungau (S)

Department of Pharmacy, University of Oradea, Oradea, Romania.

Aura-Mihaela Lupu (AM)

Department of Radiology, Brasov CF General Hospital, Brasov, Romania.

Camelia C Scarneciu (CC)

Department of Fundamental, Prophylactic and Clinical Disciplines, "Transilvania" University of Brasov, Brasov, Romania.

Ovidiu Gabriel Bratu (OG)

Clinical Department 3, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.

Orsolya Martha (O)

Clinical Department of Surgery M5, University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania.

Delia Mirela Tit (DM)

Department of Pharmacy, University of Oradea, Oradea, Romania.

Lotfi Aleya (L)

Laboratoire Chrono-environnement, CNRS 6249 Université de Franche-Comté, Besançon, France. Electronic address: lotfi.aleya@univ-fcomte.fr.

Sorin Lupu (S)

Clinic of Urology, Brasov Emergency Clinical Hospital, Brasov, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH